Tekla Capital Management LLC Neurocrine Biosciences Inc Transaction History

Tekla Capital Management LLC

$2.53 Billion
Q2 2023

A detailed history of Tekla Capital Management LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Tekla Capital Management LLC holds 112,908 shares of NBIX stock, worth $14.2 Million. This represents 0.42% of its overall portfolio holdings.

Number of Shares

112,908

Previous 112,908 -0.0%

Holding current value

$14.2 Million

Previous $11.4 Million 6.83%

% of portfolio

0.42%

Previous 0.44%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$106.72 - $127.06 $5.89 Million - $7.01 Million	-55,200 Reduced 32.84%	112,908 $13.5 Million
Q2 2022 Jul 29, 2022	BUY	$75.79 - $100.07 $3.3 Million - $4.35 Million	43,499 Added 34.91%	168,108 $16.4 Million
Q3 2021 Nov 12, 2021	SELL	$86.18 - $99.03 $7.61 Million - $8.74 Million	-88,282 Reduced 41.47%	124,609 $12 Million
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $7.12 Million - $9.71 Million	-81,343 Reduced 27.65%	212,891 $20.7 Million
Q4 2020 Feb 12, 2021	BUY	$86.91 - $108.33 $20.1 Million - $25 Million	231,031 Added 365.54%	294,234 $28.2 Million
Q3 2020 Nov 13, 2020	SELL	$96.16 - $135.15 $13.7 Million - $19.3 Million	-142,947 Reduced 69.34%	63,203 $6.08 Million
Q1 2020 May 14, 2020	BUY	$75.11 - $113.76 $984,541 - $1.49 Million	13,108 Added 6.79%	206,150 $17.8 Million
Q4 2019 Feb 13, 2020	SELL	$86.8 - $118.57 $1.2 Million - $1.63 Million	-13,780 Reduced 6.66%	193,042 $20.8 Million
Q3 2019 Nov 13, 2019	SELL	$83.82 - $101.5 $21,457 - $25,984	-256 Reduced 0.12%	206,822 $18.6 Million
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $1.05 Million - $1.33 Million	-14,600 Reduced 6.59%	207,078 $17.5 Million
Q1 2019 May 14, 2019	BUY	$69.31 - $91.53 $373,165 - $492,797	5,384 Added 2.49%	221,678 $19.5 Million
Q4 2018 Feb 13, 2019	BUY	$68.32 - $124.36 $250,324 - $455,655	3,664 Added 1.72%	216,294 $15.4 Million
Q3 2018 Nov 13, 2018	SELL	$98.88 - $125.85 $5.65 Million - $7.19 Million	-57,139 Reduced 21.18%	212,630 $26.1 Million
Q2 2018 Aug 13, 2018	SELL	$75.3 - $105.99 $726,645 - $1.02 Million	-9,650 Reduced 3.45%	269,769 $26.5 Million
Q1 2018 May 14, 2018	SELL	$75.88 - $92.43 $3.46 Million - $4.22 Million	-45,648 Reduced 14.04%	279,419 $23.2 Million
Q4 2017 Feb 14, 2018	SELL	$58.53 - $77.59 $13.9 Million - $18.4 Million	-237,400 Reduced 42.21%	325,067 $25.2 Million
Q2 2017 Aug 14, 2017	BUY	N/A	562,467	562,467 $25.9 Million

Others Institutions Holding NBIX

# of Institutions

629

Shares Held

94.2M

Call Options Held

692K

Put Options Held

406K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tekla Capital Management LLC with notifications on news.

Account

Tekla Capital Management LLC Neurocrine Biosciences Inc Transaction History